Project Grant R01AI189230
Award Date
4/23/25
Completion Date
3/31/30
Dollars Obligated
$625K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $234,113 to The University of Texas Southwestern Medical Center to conduct research on defining the epigenetic landscape at the HIV-1 provirus 3'-end. The goal of this exploratory and developmental grant is to investigate two possible models on the function of the histone modification H3K9me3 at the HIV-1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) in the amount of $285,816. The objective of this 3-year grant, with a project period from September 12, 2024 to October 31, 2027, is to enhance the understanding of ADP-ribosylation (ADPR) in the context of HIV-1 latency and reactivation. The research aims to identify...
This Project Grant award, with a total funding amount of $220,224.00 from the National Institute of Allergy and Infectious Diseases (NIAID), supports computational investigations into the assembly, maturation, and uncoating processes of the HIV-1 virus. The research, conducted by the University of Chicago, aims to provide a mechanistic understanding of these critical morphological transitions, which could aid in the design of future antiretroviral therapies. The project focuses on examining...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance understanding of host-viral dynamics and potential therapeutic strategies for HIV eradication. The $794,045 award supports research at the University of California, San Francisco (UCSF) to investigate the role of class II cytokines, such as IL-10 and interferons, in controlling HIV across...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,837,312.93 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct research on the biochemistry and regulation of the SAMHD1 protein and its role in innate immune defense against HIV-1 infection. The key objectives of this 5-year project are to: 1) Delineate how the enzymatic...
This federal Project Grant award provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program, totaling $205,153, will fund research to investigate the potential role of pulmonary arterial smooth muscle cells (PVSMC) as reservoirs for HIV. The research aims to determine PVSMC's ability to sustain chronic HIV infection and spread the virus to other immune cells during antiretroviral therapy (ART)....
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $243,713 to the University of Massachusetts Medical School to conduct research on mechanisms of HIV persistence in macrophages. The goal is to determine how HIV-infected macrophages resist antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells, which could inform more effective HIV...
This $145,642 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under its Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Emory University to develop virus-like particle (VLP) delivery systems for a novel HIV-1 cure strategy. The key objectives are to: 1) utilize VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, employing a "shock and kill" approach where reactivated cells are...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $872,684 to Yale University to conduct research on HIV persistence and HIV-induced inflammation in tissues. The goal is to use single-cell multi-omic profiling to identify and examine the heterogeneous population of transcriptionally active HIV-infected cells, with the aim of understanding how these cells drive...
This $550,620 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at the University of Florida to investigate the role of a unique family of transcription factors, called pioneer factors, in regulating HIV transcription and latency. The key objectives are to: Screen a library of short hairpin RNAs (shRNAs) targeting 31 pioneer factors to identify those that impact HIV...